Management of Heavy Menstrual Bleeding in Women Receiving Antiplatelet Therapy

AHA/ACC Recommendations

The American Heart Association recommends that tranexamic acid be avoided in women with heavy menstrual bleeding who are taking clopidogrel for secondary prevention after myocardial infarction because the thrombotic risk outweighs any menstrual‑bleeding benefit. 1
The American Heart Association also advises against tranexamic acid in women with spontaneous coronary artery dissection (SCAD); this principle extends to all women with established coronary artery disease, where the drug’s thrombotic risk supersedes its potential bleeding‑control advantage. 2

According to American College of Cardiology/American Heart Association (ACC/AHA) guidelines, clopidogrel is recommended for up to 12 months after an acute coronary syndrome or after percutaneous coronary intervention with stent placement (Class I recommendation). 3

The levonorgestrel‑releasing intrauterine device (20 µg/day) is the most effective medical option for heavy menstrual bleeding, decreasing menstrual blood loss by approximately 71–95 % while providing primarily local hormonal effects. (Expert consensus) 1
This levonorgestrel IUD is the only progestin‑containing intrauterine device evaluated for heavy menstrual bleeding and demonstrates efficacy comparable to endometrial ablation. (Expert consensus) 2
Cyclic oral progestin therapy can reduce menstrual bleeding by about 87 %; however, theoretical safety concerns exist in patients with cardiovascular disease. (Expert consensus) 1
Endometrial ablation techniques (thermal balloon, microwave, radiofrequency) provide greater long‑term bleeding control than oral medical therapies and avoid the risk of pregnancy. (Expert consensus) 2

Tranexamic acid should be reserved only for cases where all alternative treatments have failed or are contraindicated, the bleeding is severe enough to cause hemodynamic instability, the patient has been fully counseled about the heightened thrombotic risk, and close monitoring for thrombotic complications can be ensured. (ACC guidance; expert consensus) [3][1]

Non‑steroidal anti‑inflammatory drugs (NSAIDs) should be avoided in this population because they are linked to myocardial infarction and thrombosis in patients with cardiovascular disease. (Expert consensus) 2
Hormonal contraceptives carry relative contraindications in women with established coronary disease due to thrombotic activation, whereas the levonorgestrel IUD has minimal systemic absorption and is therefore safer. (Expert consensus) 1

While tranexamic acid can reduce menstrual blood loss by 26–60 % and improve quality of life in women without cardiovascular disease, the potential mortality risk from recurrent myocardial infarction or other thrombotic events in women with coronary disease takes precedence over these benefits. (Expert consensus) 2
The levonorgestrel IUD provides comparable reductions in menstrual bleeding without the associated thrombotic risk profile of tranexamic acid. (Expert consensus) 1